Science News Roundup: Akcea Therapeutics genetic disease treatment gets FDA approval

Following is a summary of current science news briefs.

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals, which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy.